Become a Kingdom Advisor. Experience world-class training and set yourself apart from your peers. Kingdom Advisors are men and women becoming specialists in offering biblically wise financial advice. Join today to begin your journey to integrate faith and finance.
|I’m a member.||Login to my Account|
|I’d like to join.||Join as a Member|
|I’m just visiting.||Back to Resources|
There are essentially only three reasons people object to BRI: 1) They don’t believe they’re morally responsible for the actions of the companies in their portfolios, 2) They don’t believe their investment dollars make an appreciable difference in the world, and/or 3) They believe BRI will cause them to underperform. This session examines the validity of each of these objections head-on. This session is presented by Finny Kuruvilla, MD, PhD, the Harvard-educated lead portfolio manager for the Eventide Gilead Fund, a Morningstar Five-Star fund.
Finny Kuruvilla, MD, PhD, serves as co-Chief Investment Officer and Portfolio Manager for Eventide. Dr. Kuruvilla has a unique background in healthcare, statistics, and investing. Concurrent with Eventide, from 2008 through 2016, he was a principal at Clarus Ventures, a leading healthcare and life sciences venture capital firm. Prior to joining Eventide, from 2005-2008, he was a postdoctoral research scientist in medical genetics at the Broad Institute of Harvard and MIT. From 2003-2007, he was resident, chief resident, and clinical fellow at the Brigham and Women’s Hospital and Children’s Hospital Boston. Dr. Kuruvilla holds an MD from Harvard Medical School, a PhD in Chemistry and Chemical Biology from Harvard University, a master’s degree in Electrical Engineering and Computer Science from MIT, and a bachelor’s degree in Chemistry from Caltech.